* Ocular Therapeutix Inc reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -17 cents. The mean expectation of nine analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -30 cents to -21 cents per share.

* Revenue rose 2.3% to $15.43 million from a year ago; analysts expected $17.14 million.

* Ocular Therapeutix Inc's reported EPS for the quarter was a loss of 22 cents​.

* The company reported a quarterly loss of $36.49 million.

* Ocular Therapeutix Inc shares had risen by 21.8% this quarter and gained 137.7% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 0.6% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Ocular Therapeutix Inc is 16.00 This summary was machine generated from LSEG data November 14 at 02:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.24 -0.22 Beat

Jun. 30 2024 -0.22 -0.26 Missed

Mar. 31 2024 -0.19 -0.70 Missed

Dec. 31 2023 -0.30 -0.35 Missed